Our latest articles

Vantage logo

Novo makes a gene editing move

Today’s collaboration with Life Edit is a return to the Danish group’s familiar small, early-stage deal strategy.

Vantage logo

Sanofi seeks to build on COPD win

Full Dupixent data confirm the drug’s blockbuster potential in the lung disease, but the French drug maker is thinking even bigger.

Vantage logo

Here come the PD-1 agonists

Lilly shows that peresolimab is a goer, and others are not far behind; but what about the cancer risk?